Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):112-116.

Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.

Author information

1
*Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Laboratory of Immunoregulation, NIAID, NIH, Baltimore, MD; ‡Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC; §Vaccine and Infectious Disease Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‖Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; ¶Genomics Unit, Research Technologies Section, Rocky Mountain Laboratories, DIR, NIAID, NIH, Hamilton, MT; #Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; **Science Facilitation Department, FHI360, Washington, DC; ††Science Facilitation Department, FHI360, Durham, NC; ‡‡College of Medicine-Johns Hopkins Project, Blantyre, Malawi; §§UNC Project, Lilongwe, Malawi; ‖‖Department of Medicine, University of Zimbabwe, Harare, Zimbabwe; ¶¶HIV Research Branch, Center for Global Health, Kenya Medical Research Institute (KEMRI)-Centers for Disease Control (CDC), Kisumu, Kenya; ##BHHRL & Clinical Trials Unit, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; ***Soweto HPTN CRS, Chris Hani Baragwanath Hospital, Soweto, South Africa; †††YRGCARE Medical Centre, Chennai, India; ‡‡‡Center for AIDS and STDs, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; §§§Hospital Nossa Senhora da Conceição, Serviço de Infectologia, Porto Alegre, Brazil; ‖‖‖Hospital Geral de Nova Iguaçu and Laboratorio de AIDS e Imunologia Molecular (IOC/Fiocruz), Rio de Janeiro, Brazil; ¶¶¶Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Rio de Janeiro, Brazil; ###Fenway Health and Infectious Disease Division, The Fenway Institute, Boston, MA; ****Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA; ††††Vaccine and Infectious Disease Division and Public Health Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‡‡‡‡Department of Biostatistics, University of Washington, Seattle, WA; and §§§§Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Abstract

HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART.

PMID:
27532476
PMCID:
PMC5140698
DOI:
10.1097/QAI.0000000000001158
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Conflict of Interests None of the authors has a financial or personal relationship with other people or organizations that could inappropriately influence (bias) their work. The following relationship is noted: SHE has collaborated with Abbott Diagnostics (distributor of the ViroSeq HIV Genotyping System) on evaluation of HIV-related assays.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center